Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de estudo
País como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Int Wound J ; 6(2): 159-66, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19432666

RESUMO

OBJECTIVE: To evaluate the efficacy and safety of recombinant human epidermal growth factor (rh-EGF) in healing foot ulcers in diabetic patients. METHODS: A total of 28 subjects with foot ulcers were recruited into the pilot study. Patients who had obvious peripheral arterial disease, trans-tibial amputation, plastic surgery or skin flap, and skin graft were excluded. The properly debrided wounds and the non closure wounds after toe amputation were included. When the wounds became clean or uninfected, they received twice-a-day treatment with 0.005% Easyef and hydrocolloid dressing. The size and severity of the wounds were evaluated. Others such as blood sugar, renal and hepatic function, serum albumin, vascular condition, foot infection or osteomyelitis were assessed. RESULTS: All of 28 patients had positive response of granulation (100%). Complete healing was noted in 13 out of 23 subjects and finished 8-week follow-up (56.5%). The rates of wound closure were 43.3%, 59.9%, 68.7%, and 84.8% in week 2, 4, 6 and 8, respectively, regardless of the severity. Being dropped out, three patients needed further interventions. No skin allergic reaction. Over-granulation was observed in one female patient (3.7%), but as minor. CONCLUSIONS: Easyef has positive effects on healing of moderate-to-severe foot ulcers and demonstrated being safe to diabetic patients. The drug had high tolerability and compliance.


Assuntos
Pé Diabético/tratamento farmacológico , Fator de Crescimento Epidérmico/administração & dosagem , Proteínas Recombinantes/administração & dosagem , Cicatrização , Administração Tópica , Idoso , Desbridamento , Pé Diabético/cirurgia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto
3.
Int J Endocrinol ; 2018: 7965346, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30123266

RESUMO

BACKGROUND: HLA-B∗38:02 has been shown to be associated with antithyroid drug-induced agranulocytosis in Asian patients. METHODS: HLA-B∗38:02 was analyzed by sequence-based typing in 21 patients who developed antithyroid drug-induced agranulocytosis and in 81 controls. RESULTS: Frequency of HLA-B∗38:02 was 52.4% in agranulocytosis patients compared to 3.7% in controls (OR = 28.6, 95% CI = 6.8-120.2). CONCLUSIONS: HLA-B∗38:02 is a significant risk factor for agranulocytosis in Kinh Vietnamese patients treated with antithyroid drug.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa